Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251004 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 833
- Enrollment target
NCT00251004 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 833 participants.
The verdict
NCT00251004, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 833 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
Interventions
- DRUG Everolimus
- DRUG Corticosteroids
- DRUG Basiliximab
- DRUG Cyclosporine A (CsA)
- DRUG Mycophenolic Acid (MPA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251004
The ClinicalTrials.gov registry entry for NCT00251004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Everolimus is the first listed.
NCT00251004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251004 about?
NCT00251004 is a clinical study titled "Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients". The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
What is the current status of trial NCT00251004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 833 participants. The study started on 2005-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00251004?
The interventions under investigation include: Everolimus (DRUG), Corticosteroids (DRUG), Basiliximab (DRUG), Cyclosporine A (CsA) (DRUG), Mycophenolic Acid (MPA) (DRUG).
Who is sponsoring clinical trial NCT00251004?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.